MedPath

Luminopia One Amblyopia Vision Improvement Study

Not Applicable
Completed
Conditions
Amblyopia
Interventions
Device: Refractive Correction
Device: Luminopia One
Registration Number
NCT03608150
Lead Sponsor
Luminopia
Brief Summary

The objective of the study is to demonstrate the safety and efficacy of Luminopia One in amblyopia patients with amblyopia associated with anisometropia and/or with mild strabismus.

Detailed Description

The proposed study is a multi-center randomized controlled clinical trial which compares the mean change in amblyopic eye Best Corrected Visual Acuity from baseline with Luminopia One ("therapeutic") to refractive correction ("control"). One-hundred and forty participants (n = 140) aged 4-7 years will be enrolled. Participants will be randomized 1:1 to the "therapeutic group ", to use Luminopia One, or the "control group", to undergo continued refractive correction, for 12 weeks of treatment.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
117
Inclusion Criteria
  • Age 4 to 7 years at the time of consent.
  • Amblyopia associated with anisometropia and/or mild strabismus.
  • Current refractive correction worn for at least 16 weeks or until 2 consecutive visual acuity measurements at least 8 weeks apart do not change by more than 1 logMAR lines.
  • Amblyopic eye best-corrected visual acuity (BCVA) 20/40 to 20/200 inclusive.
  • Fellow eye BCVA 20/32 or better.
  • Interocular difference ≥ 3 logMAR lines.
  • Heterotropia ≤ 5 prism diopters in current refractive correction at distance measured by SPCT.
Exclusion Criteria
  • Atropine treatment in the past 2 weeks.
  • Prior amblyopia treatment (other than refractive correction) for > 12 months in total.
  • High myopia, previous intraocular / refractive surgery, severe ocular co-morbidities or development / cognitive delay.
  • History of low adherence with amblyopia treatment or light-induced seizures.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Control GroupRefractive CorrectionParticipants assigned to the control group will wear their current refractive correction full-time for 12 weeks.
Therapeutic GroupLuminopia OneParticipants assigned to the therapeutic group will be prescribed Luminopia One for 1 hour per day, 6 days per week for 12 weeks.
Primary Outcome Measures
NameTimeMethod
Best-Corrected Visual Acuity of Fellow Eye12 weeks

Mean improvement in best-corrected visual acuity of fellow eye from baseline after 12 weeks of treatment using electronic ATS-HOTV protocol.

Best-Corrected Visual Acuity of Amblyopic Eye12 weeks

Mean improvement in best-corrected visual acuity of amblyopic eye from baseline after 12 weeks of treatment using electronic ATS-HOTV protocol.

Secondary Outcome Measures
NameTimeMethod
Stereoacuity12 weeks

Mean stereoacuity improvement from baseline after 12 weeks.

Adherence12 weeks

Mean adherence with the therapeutic in treatment group.

Best-Corrected Visual Acuity of Amblyopic Eye8 weeks

Mean improvement in best-corrected visual acuity of amblyopic eye from baseline after 8 weeks using electronic ATS-HOTV protocol.

Trial Locations

Locations (21)

Cleveland Clinic

🇺🇸

Cleveland, Ohio, United States

Texas Children's Hospital (BCM)

🇺🇸

Houston, Texas, United States

UCLA Jules Stein Eye Institute

🇺🇸

Los Angeles, California, United States

Lurie Children's Hospital

🇺🇸

Chicago, Illinois, United States

Eye Physicians of Central Florida

🇺🇸

Maitland, Florida, United States

IU School of Optometry

🇺🇸

Bloomington, Indiana, United States

Kids Eye Care of Maryland

🇺🇸

Frederick, Maryland, United States

Children's Eye Care of Michigan

🇺🇸

Dearborn, Michigan, United States

Saint Louis University

🇺🇸

Saint Louis, Missouri, United States

OSU College of Optometry

🇺🇸

Columbus, Ohio, United States

Conestoga Eye

🇺🇸

Lancaster, Pennsylvania, United States

Pediatric Ophthalmology of Erie

🇺🇸

Erie, Pennsylvania, United States

Children's Hospital Of Philadelphia

🇺🇸

Philadelphia, Pennsylvania, United States

Tri-County Eye Physicians

🇺🇸

Southampton, Pennsylvania, United States

Houston Eye Associates

🇺🇸

Houston, Texas, United States

Virginia Pediatric Eye Center

🇺🇸

Virginia Beach, Virginia, United States

Specialized Pediatric Eye Care

🇺🇸

Beverly, Massachusetts, United States

Duke University

🇺🇸

Durham, North Carolina, United States

University of Nebraska Medical Center

🇺🇸

Omaha, Nebraska, United States

Rocky Mountain Eye Care

🇺🇸

Salt Lake City, Utah, United States

Family Focus Eye Care

🇺🇸

Gainesville, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath